Navigation Links
Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
Date:11/15/2010

mersen (a.k.a. RB007).

Both abstracts were coauthored by Steven L. Zelenkofske, D.O., Christopher P. Rusconi, Ph.D., Carolyn M. Darmiento, MS, all from Regado Biosciences; and Richard C. Becker, MD, Duke University School of Medicine, Durham, NC; Thomas L. Ortel, M.D., Ph.D., Director, Duke Clinical Coagulation and Platelet Immunology Laboratories; and William Wargin, Ph.D. President of PK-PM Associates, LLC.

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics (including anticoagulants and antiplatelet agents) in the acute and sub-acute care cardiovascular setting, a multi-billion dollar world-wide market in need of drugs with improved safety profiles and a greater degree of therapeutic control.  The products in Regado's pipeline are designed to act as optimized antithrombotics, uniquely concomitantly minimizing the risk of ischemia and bleeding, and, by allowing patient specific tuning of the desired therapeutic effect, providing a safe and unique approach to personalized medicine.

ABOUT REG1, REG2 and REG3  Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (pegnivacogin, a.k.a. RB006) and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, presently in a phase 2b clinical trial (the RADAR trial), is i
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
2. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
3. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
4. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
5. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
6. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
7. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
8. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
9. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
10. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
11. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 2015 Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... the upcoming Rodman & Renshaw 17 th Annual ... New York City .  Dr. ... corporate overview on September 9, 2015. ...
(Date:9/4/2015)... Sep. 04, 2015 ... the addition of the "Pharmacovigilance (London, UK ... offering. Understanding PhV today - the ... working in Drug safety. This course ... with pharmacovigilance. New entrants as well as experienced ...
(Date:9/4/2015)... Sep. 04, 2015 ... has announced the addition of the ... 2010-2019" report to their offering. ... containing repeating disaccharide units of Na-glucuronate-N-acetylglucosamine. As ... cartilage matrix, sodium hyaluronate can lubricate the ...
Breaking Medicine Technology:Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2Investigation Report on China's Sodium Hyaluronate Market 2015 2
... 1 October is American Pharmacists Month and ... provide outstanding care to their patients every day ... specialty pharmacies across the country. (Logo: ... Pharmacists Month is a time to recognize the ...
... national initiative, the Pediatric Trials Network (PTN), was created ... the National Institutes of Health (NIH).  The PTN will ... Shriver National Institute of Child Health and Human ... medical centers, including Children,s Mercy Hospitals and Clinics.   ...
Cached Medicine Technology:CVS Caremark Recognizes Its 26,000 Pharmacists During October's American Pharmacists Month 2New National Program to Study and Establish Pediatric Dosing 2New National Program to Study and Establish Pediatric Dosing 3
(Date:9/4/2015)... ... 2015 , ... According to an article published August 4th by ... data showing that it is safe for pregnant women to undergo local anesthesia needed ... local anesthesia with a group that hadn’t, researchers were able to determine that “local ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group filed an ... , Schmidt National Law Group, a leading firm in mass-tort litigation, has filed ... Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to have been ...
(Date:9/4/2015)... Marietta, GA (PRWEB) , ... September 04, 2015 , ... ... team is in desperate need of new apparel. In an effort to assist the ... around Marietta, has launched a charity drive to raise funds for the new uniforms. ...
(Date:9/4/2015)... Valley Forge, PA (PRWEB) , ... September 04, 2015 , ... ... mold growth in and around the home is quite common. Mold can grow anywhere ... as areas around leaking pipes. Checking for excessive moisture and water in the home ...
(Date:9/4/2015)... , ... September 04, 2015 , ... Many consumers are looking for a quick and ... their solution. , The patent-pending K Med Cups provide a quick and simple way to ... relieve a cold, flu or cough. As a result, they enhance comfort and health. The ...
Breaking Medicine News(10 mins):Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 2Health News:The Jones Agency Serves Up a Charity Drive to Fund New Uniforms for the Sprayberry High School Girls Volleyball Team 3Health News:September is Mold Awareness Month 2Health News:September is Mold Awareness Month 3Health News:September is Mold Awareness Month 4Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2
... that head and neck cancer treatments fail is the tumor ... University of Michigan Comprehensive Cancer Center have found that a ... overcome that resistance. When researchers added a curcumin-based ... they were able to cut the dose of the chemotherapy ...
... A University of Missouri researcher has found that eating ... satiety and reduces hunger throughout the day. In addition, ... that eating a protein-rich breakfast reduces the brain signals ... knows that eating breakfast is important, but many people ...
... Barcelona researchers have discovered that Viagra drastically reduces multiple ... research, published in Acta Neuropathologica , demonstrates that ... animals after eight days of treatment. Researchers are confident ... patients given that the drug is well tolerated and ...
... The American Society of Clinical Oncology (ASCO) today ... more than 4,000 abstracts publicly posted online at www.asco.org ... additional 17 plenary, late-breaking and other major studies will ... Meeting. The meeting, which is expected ...
... , THURSDAY, May 19 (HealthDay News) -- Problem gambling ... especially online, of gambling opportunities, said experts who called ... the disorder. While most people gamble as an ... too seriously involved in terms of time invested and ...
... RECOMMENDS WAYS TO ENSURE ACCESS TO AFFORDABLE INSURANCE IS ... Combined Small Business and Individual Health Insurance Exchanges Could ... New York, NY, May 19, 2011Modifications to current policies ... provided under the Affordable Care Act remain stable even ...
Cached Medicine News:Health News:Curcumin compound improves effectiveness of head and neck cancer treatment, U-M study finds 2Health News:Eat a protein-rich breakfast to reduce food cravings, prevent overeating later, researcher finds 2Health News:Viagra could reduce multiple sclerosis symptoms 2Health News:ASCO releases studies from upcoming annual meeting 2Health News:ASCO releases studies from upcoming annual meeting 3Health News:Internet Is Playing a Part in Spread of Problem Gambling 2Health News:New report on health reform implementation: How to ensure access to coverage is maintained 2Health News:New report on health reform implementation: How to ensure access to coverage is maintained 3
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
... Coronary Stent System is Guidant's first in ... Cobalt chromium is stronger and more radiopaque ... stent can have similar strength and visibility ... struts that are only .0032" thick. Thinner ...
Medicine Products: